AN2 Therapeutics

ANTX · NASDAQ

$3.56+$0.19 (+5.64%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $3.37

ANTX analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy2
Hold0
Underperform0
Sell0

12-month price target · 4 analysts

Average $9.18 (+157.9% upside)

Low: $9.09
Now: $3.56
High: $9.45

Upgrades and downgrades

The latest rating actions, newest first

ANTX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Guggenheim	Jul 20, 2026	Initiates	Buy	$9.00	46%
Leerink Partners	May 14, 2026	Upgrade	Market Perform → Outperform	$9.00	34%

The case for and against

Updated Oct 23, 2025

Bull case

AN2 Therapeutics Inc. has demonstrated significant promise in its drug development pipeline, particularly with AN2-502998, which achieved 100% survival in non-human primate models for Chagas disease, surpassing previously developed agents from established pharmaceutical companies. The recognition of unmet medical needs in diseases such as Chagas and melioidosis further enhances the strategic importance of AN2's therapeutic candidates. Although additional safety data from human trials is required for comprehensive valuation, the company's innovative boron-based compounds and positive preclinical results point toward a favorable long-term outlook for AN2 Therapeutics's stock.

Bear case

AN2 Therapeutics Inc has a persistent history of financial losses and lacks a proven track record of profitability, raising concerns about its long-term viability. The company's ability to successfully partner for favorable terms is uncertain, which could jeopardize the success of any potential commercial launch. Additionally, the risks associated with the efficacy and safety of its drug candidates in clinical development could hinder approval and commercialization efforts, further complicating its financial outlook.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.